Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | METAP2 | P50579 | 4/20 | 0.50 |
| ▸ | PDK2 | Q15119 | 9/20 | 0.43 |
| ▸ | PIK3CD | O00329 | 3/20 | 0.42 |
| ▸ | PIK3CG | P48736 | 3/20 | 0.42 |
| ▸ | PIK3R2 | O00459 | 1/20 | 0.42 |
| ▸ | GRM2 | Q14416 | 2/20 | 0.41 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
| ▸ | CTSD | P07339 | 1/20 | 0.41 |
| ▸ | BACE1 | P56817 | 1/20 | 0.41 |
| ▸ | BACE2 | Q9Y5Z0 | 1/20 | 0.41 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.39 |
| ▸ | MTOR | P42345 | 2/20 | 0.39 |
| ▸ | LCK | P06239 | 1/20 | 0.39 |
| ▸ | BTK | Q06187 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22612487 | 0.80 | KIT (0.42) | METAP2PDK2PIK3CDLCKBTK | |
| SCHEMBL31182220 | 0.80 | PDK2 (0.44) | METAP2PDK2PIK3CDPIK3CGPIK3CB | |
| SCHEMBL15408022 | 0.77 | LCK (0.58) | PDK2PIK3CDGRM2LCKBTK | |
| SCHEMBL29643048 | 0.76 | PSMD14 (0.47) | PDK2PIK3CDPIK3CGPIK3R2GRM2 | |
| SCHEMBL30023798 | 0.76 | FFAR1 (0.47) | METAP2PDK2LCKBTK | |
| SCHEMBL29743564 | 0.74 | PDK2 (0.46) | METAP2PDK2 | |
| SCHEMBL15408581 | 0.74 | METAP2 (0.51) | METAP2 | |
| SCHEMBL29480681 | 0.73 | LRRK2 (0.44) | PDK2PIK3CDPIK3CGCTSDBACE1 | |
| SCHEMBL31156545 | 0.72 | L3MBTL1 (0.41) | PDK2PIK3R2GRM2NR1I2KCNH2 | |
| SCHEMBL29859763 | 0.72 | CLK2 (0.48) | PDK2GRM2NR1I2KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240308980-A1 | HETEROARYL AMIDES AS LRRK2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | MERCK SHARP & DOHME LLC (US) | 2024-09-19 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240308980-A1 | HETEROARYL AMIDES AS LRRK2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | LRRK2, CLK2, BRSK2 | METAP2 2544/4885PDK2 102/4885PIK3CD 444/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.